In breast cancer, the phase III OlympiAD and EMBRACA trials demonstrated significantly improved progression-free survival with olaparib and talazoparib, respectively, compared to standard chemotherapy in patients with HER2-negative, germline BRCA1/2-mutated metastatic disease (19–21). This evidence concerns the gene ERBB2 and breast carcinoma.